Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
$500,000 Endowment Gift from The GlaxoSmithKline Foundation Expands Program to Help Patients with Cancer and their Families at The Children's Hospital of Philadelphia
Publish date: Mar 18, 2013
![]()
PR Newswire PHILADELPHIA, March 18, 2013
Donation Will Enable Patients and Families with Limited Financial Means to Benefit from Cutting-Edge Cancer Research and
Treatments at Children's Hospital
PHILADELPHIA, March 18, 2013 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia is proud to announce a $500,000 gift from the GlaxoSmithKline (GSK) Foundation. The donation will greatly enhance the GlaxoSmithKline
Hope for Families Fund, an endowment fund which was established in 2008 with a $1 million gift
from The GlaxoSmithKline Foundation and GlaxoSmithKline, and matched by The Children's Hospital of Philadelphia.
This Fund provides vital assistance to financially eligible families that need assistance for travel and living expenses they
may incur while their child is enrolled in investigational and/or novel treatments offered at the Cancer Center at Children's
Hospital. View an infographic about the Hope for Families Fund. (Photo: http://photos.prnewswire.com/prnh/20130318/DC78720-INFO)
"Financial burdens such as missed time from work, airfare and other expenses can really take a big toll on a family dealing
with cancer," said Paolo Paoletti, M.D., president, GlaxoSmithKline Oncology. "Through the
GSK Hope for Families Fund, our goal is to alleviate some of the financial burden so that families can focus on helping their
child get well." The GlaxoSmithKline Hope for Families Fund is a permanent endowment that helps children and young adults with relapsed cancers gain access to innovative therapies at Children's Hospital. Specifically, the Fund reimburses
the families for expenses related to their travel and stay in Philadelphia, including airfare
and ground transportation, lodging, and meals. "The generosity of GlaxoSmithKline has relieved many boundaries to care and has allowed families to get the world's best
treatment for pediatric cancers at The Children's Hospital of Philadelphia," said Steven
M. Altschuler, M.D., chief executive officer of The Children's Hospital of Philadelphia.
"By growing the Fund, we will be able to help even more families access innovative treatments and the care offered here." Since July 1, 2008, the GSK Hope for Families Fund has assisted 94 families with travel and
living expenses relating to assessment for and/or enrollment in clinical trials at The Children's Hospital of Philadelphia's
Cancer Center. Families have come from 20 U.S. states and six foreign countries. The youngest patient helped was three years
old and the oldest was 27. Many families using the Fund are low-income or one-income families, and there has been increased usage of the Fund due
to the worsening economy. Many parents do not get paid if they have to take days off while their child is receiving treatment
for their cancer. This is an acute burden, as many of the patients enrolled in clinical trials are required to come to Children's
Hospital frequently, sometimes as often as weekly, over a long period of time. Each year, more families need assistance, and this new gift from the GlaxoSmithKline Foundation will allow Children's Hospital
social workers to better meet the growing need. Additionally, the GSK Hope for Families Fund has supported qualifying international
families.
The Cancer Center at Children's Hospital has been ranked #1 in the country by U.S. News & World Report and Parents
magazine. With the largest developmental therapeutics program in the United States, the Cancer
Center and its Center for Childhood Cancer Research are beacons of hope for families around the globe, providing advanced
treatments not found in most patients' home healthcare institutions. "Recently, our program has focused heavily on developing new drugs for childhood cancer, and the national referral-basis
for these unique clinical trials led to the need for a program such as the Hope for Families Fund," said John
M. Maris, M.D., director of the Center for Childhood Cancer Research at Children's Hospital. "Therefore with the help
of the funds from the GlaxoSmithKline Foundation, Children's Hospital is moving one step closer to ensuring all children with
cancer are provided the best possible care." "Corporate philanthropy is critical to furthering our mission to provide the very best family-centered care possible,"
Altschuler said. "We are extremely grateful to the GlaxoSmithKline Foundation for this remarkable donation." The Cancer Center at Children's Hospital is a Phase I institution and leader within the Children's Oncology Group. The
Center strives to provide the most skilled, compassionate care available. State-of-the-art facilities enable it to
offer comprehensive, family-centered care from 69 nationally and internationally renowned pediatric oncologists and specialists.
Their combined expertise spans every major form of childhood cancer. Each year, the Cancer Center treats more than 500 new
patients and follows nearly 5,000 patients, making the program one of the largest pediatric cancer programs in the world.
GSK has been a steadfast philanthropic partner to the community and The Children's Hospital of Philadelphia
is grateful for the difference GSK's support has made to our patients and families.
About GlaxoSmithKline: One of the world's leading research-based pharmaceutical and healthcare companies, GSK is committed
to improving the quality of human life by enabling people to do more, feel better and live longer. For further information
go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog:
www.morethanmedicine.us.gsk.com/blog/. The GlaxoSmithKline Foundation, which was established in 1990, administers the employee matching gifts program for charitable
organizations. It also has provided select endowment gifts to support the health and education needs at the local community
level.
About The Children's Hospital of Philadelphia: Founded in 1855, The Children's Hospital
of Philadelphia is the birthplace of pediatric medicine in America. Throughout its history,
a passionate spirit of innovation has driven this renowned institution to pursue scientific discovery, establish the highest
standards of patient care, train future leaders in pediatrics and advocate for children's health. A haven of hope for children
and families worldwide, CHOP is a nonprofit charitable organization that relies on the generous support of its donors to continue
to set the global standard for pediatric care. For more information about The Children's Hospital of Philadelphia,
visit www.chop.edu. For information about the Cancer Center, visit www.chop.edu/cancer. To view the infographic, visit http://bit.ly/GSKInfo.
The Children's Hospital of Philadelphia
GlaxoSmithKline Foundation SOURCE The Children's Hospital of Philadelphia
|
|